RATIONALE: Penicillin allergy testing has historically been underutilized in the inpatient setting where it may directly impact treatment. We expanded penicillin allergy testing to hospitalized patients to determine the rate of penicillin hypersensitivity, the barriers of inpatient testing, and the subsequent use of beta-lactams or cephalosporins. METHODS: We evaluated 55 hospitalized patients from 9/2017-8/2018 with reported penicillin allergy that were referred by primary teams or specialists if beta-lactams or cephalosporins were desired for prophylaxis or to treat underlying infection. Qualifying patients then underwent skin testing followed by oral Amoxicillin challenge. RESULTS: 37 patients (67%) underwent testing with 35 (94%) proving to be tolerant of beta-lactams or cephalosporins. Of the patients that were tested, direct drug challenges were administered to 19 (51%) patients based on clinical history, with no reported adverse outcomes. Of the 35 tolerant patients, 25 (71%) had a beta-lactam added to their treatment, 9 (26%) received a cephalosporin, whereas 4 (11%) received other antibiotics. Barriers to testing included patients with incompatible medication use (4), clinical instability (5), or delayed symptoms (4); 4 patients declined testing. CONCLUSIONS: Our results suggest that 6% of patients with reported penicillin allergy exhibit true sensitivity, consistent with previous reports. A majority of patients were able to tolerate direct drug challenge, indicating that improved utilization of clinical history can simplify testing protocols and may prove sufficient for many patients. Additionally, most subsequent treatment plans for tested patients included a beta-lactam or cephalosporin. Despite barriers, inpatient penicillin allergy testing may decrease reported allergies and broaden antibiotic options. RESULTS: A total of 1379 cases with adverse drug reactions were screened, and 596 cases of drug rash were identified (43%). Out of these 596 cases of drug-induced rash, a total of 35 (5.9%) cases of SCARS were encountered (M: F ratio; 1.06:1.0; mean age of 48.5 year). Of those 35 cases, 32 were Caucasian (91.4%). The most common manifestations were DRESS (19/ 54.3%), SJS (8/ 22.8%), AGEP (6/ 17.1%), TEN (1/ 2.9%), and OL (1/ 2.9%). The most common drugs implicated were antibiotics (93.5%). Among the 10 cases of SJS/TEN/Overlap syndrome, trimethoprim/sulfamethoxazole (40%) was the most common causative agents. In DRESS, amoxicillin (26.3%) and ciprofloxacin (26.3%) together accounted for 52.6% of the cases. Twenty-five of the 35 patients with SCARs were hospitalized. Most of the patients with SCARs were given triamcinolone cream and prednisone alone (18/ 51.4%), methylprednisolone alone (1/2.9%), methylprednisolone/prednisone combined (4/11.4%), Department of Internal Medicine, Korea University Medical Center Anam Hospital, Seoul, Korea, 4 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South). RATIONALE: The frequency of delayed reactions to radiocontrast media(RCM) occurred in approximately 0.5-23.0% of patients and the majority of these reactions are thought to be due to T cell mediated mechanisms. However, optimal pretreatment regimen is not established and there are not enough data to support the efficacy of premedication in patients with delayed reactions to RCM. METHODS: A retrospective chart review was conducted on 29 patients with previous delayed hypersensitivity reactions to iodine RCM who visited the allergy clinic for the prevention of reaction in the rechallenge of RCM in Seoul National University Bundang Hospital in 2016-2017. RESULTS: The mean age was 52.2 years and 72.4% were female. The onset of reactions was 1hr to 3 days after exposure to RCM. Reaction duration was 24 hours to 3 months and 89.66% resolved in 2 weeks. All patients exhibited skin symptoms. After the delayed reactions to RCM, pretreatment was performed to patients at the next exam using RCM. As pretreatment, 21 patients received steroid and antihistamine 1 hr before RCM injection and 4 received steroid additionally 12 hrs before RCM injection. As post RCM treatment, 12 patients were given oral steroids for 2-3 days, and 18 patients were given antihistamines for 3-7 days after RCM injection. With these pretreatments, there was a symptom improvement in all patients and symptom disappeared completely in 19(65.52%) patients. CONCLUSIONS: Premedications showed beneficial effect when it is necessary and not contraindicated. Further investigations are needed to establish practical pretreatment protocol for prevention of delayed reactions to RCM. 
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